Amphisbaena

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Monday, April 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

Retrieved on: 
Wednesday, January 24, 2024
Protein, Survival, Therapy, Amphisbaena, Interim, Central nervous system, Brain, CNS, TPD, Vaccine

Rapid degradation of target protein: significant levels of degradation were induced rapidly after dosing.

Key Points: 
  • Rapid degradation of target protein: significant levels of degradation were induced rapidly after dosing.
  • Highly selective degradation of target protein: statistically significant degradation of target protein vs >8000 other proteins, including closely related homologs, when dosed at 100x DC50.
  • These data show:
    Amphista degraders can be rationally designed to achieve CNS penetrance with examples achieved across multiple targets.
  • To our knowledge, this is the first time an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader has shown efficacy in disease-relevant in vivo models.

Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders

Retrieved on: 
Wednesday, January 24, 2024
Protein, Survival, Therapy, Amphisbaena, Interim, Central nervous system, Brain, CNS, TPD, Vaccine

Rapid degradation of target protein: significant levels of degradation were induced rapidly after dosing.

Key Points: 
  • Rapid degradation of target protein: significant levels of degradation were induced rapidly after dosing.
  • Highly selective degradation of target protein: statistically significant degradation of target protein vs >8000 other proteins, including closely related homologs, when dosed at 100x DC50.
  • These data show:
    Amphista degraders can be rationally designed to achieve CNS penetrance with examples achieved across multiple targets.
  • To our knowledge, this is the first time an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader has shown efficacy in disease-relevant in vivo models.

Camena Bioscience Appoints Dr Nicola Thompson as Chair of the Board

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Environment, Health, Genetics, Green Technology, Acquisition, Cell biology, DNA, Therapy, Gene, Chair, Chairperson, Astellas Pharma, University College London, GSK, Roche, Growth, Doctor of Philosophy, Pharma, Pharmaceutical industry, Amphisbaena, Camena

Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.

Key Points: 
  • Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has appointed Dr Nicola Thompson as Chair of its Board of Directors.
  • Dr Steve Harvey, CEO, Camena Bioscience commented: "Nicola is a successful CEO and Chair and a fantastic addition to the Board.
  • Camena Bioscience enables researchers to ‘write’ DNA with the same confidence and ease with which we can ‘read’ DNA.
  • Dr Nicola Thompson, Chair of the Board, Camena Bioscience, added: “I am delighted to join the Company as its Chair at this pivotal stage of growth.

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Retrieved on: 
Tuesday, September 26, 2023
BMY, TPD, Bristol Myers Squibb, Amphisbaena, NYSE, CNS, Pharmaceutical industry

Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.

Key Points: 
  • Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for achieving the milestone.
  • This follows the announcement of the first milestone achieved in the first discovery programme on May 4, 2023 .
  • Louise Modis, Chief Scientific Officer of Amphista Therapeutics said: “The achievement of this first milestone in the second discovery programme under Amphista’s strategic collaboration with Bristol Myers Squibb is a testament to our innovative science and ability to discover and progress at pace differentiated, novel therapeutic molecules for our pharmaceutical partners.
  • Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Retrieved on: 
Thursday, May 4, 2023
BMS, Therapy, TPD, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Amphisbaena

CAMBRIDGE, England, May 4, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.

Key Points: 
  • CAMBRIDGE, England, May 4, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.
  • Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS.
  • Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys™, its next-generation TPD platform.
  • Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

Retrieved on: 
Thursday, May 4, 2023
BMS, Therapy, TPD, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Amphisbaena

CAMBRIDGE, England, May 4, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.

Key Points: 
  • CAMBRIDGE, England, May 4, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the delivery of the first discovery milestone under its collaboration and license agreement with Bristol Myers Squibb, triggering a payment for achieving the milestone.
  • Nicola Thompson, CEO of Amphista, said, "We are absolutely delighted with the progress and success of our collaboration with BMS.
  • Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys™, its next-generation TPD platform.
  • Bristol Myers Squibb is granted a global exclusive license to the resulting degraders and will be responsible for further development and commercialization activities.

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Retrieved on: 
Tuesday, May 2, 2023
GSK, GSK plc, Therapy, EMBL, CSO, TPD, Doctor of Philosophy, Boehringer Ingelheim, Amphisbaena, Takeda Oncology, Drug discovery, Pharmaceutical industry

CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).
  • In light of this, we are expanding our senior team with the appointment of Louise.
  • Ian said, "The rapid scientific progress we have made means it is the right time to broaden our senior team.
  • I am looking forward to working with Louise as we continue to develop our technology platform and in parallel build our pipeline."

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Retrieved on: 
Tuesday, May 2, 2023
GSK, GSK plc, Therapy, EMBL, CSO, TPD, Doctor of Philosophy, Boehringer Ingelheim, Amphisbaena, Takeda Oncology, Drug discovery, Pharmaceutical industry

CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).

Key Points: 
  • CAMBRIDGE, England, May 2, 2023 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD), today announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer (CSO) and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer (CTO).
  • In light of this, we are expanding our senior team with the appointment of Louise.
  • Ian said, "The rapid scientific progress we have made means it is the right time to broaden our senior team.
  • I am looking forward to working with Louise as we continue to develop our technology platform and in parallel build our pipeline."

Pathios Therapeutics Appoints Jeanmarie Guenot, Ph.D., as Non-Executive Director

Retrieved on: 
Wednesday, November 30, 2022
Pathio District, Maverick, London Bioscience Innovation Centre, Harpoon, Therapy, Patient, Myelodysplastic syndrome, Lead, Acute leukemia, GPR65, Cancer, Research, Takeda, Drug discovery, Pharmaceutical industry, Amphisbaena

OXFORD, United Kingdom, Nov. 30, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot, Ph.D., has been appointed as a non-executive director to the company's board of directors.

Key Points: 
  • OXFORD, United Kingdom, Nov. 30, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot, Ph.D., has been appointed as a non-executive director to the company's board of directors.
  • Dr. Guenot is currently the Founder, President and Chief Executive Officer of Toreador Therapeutics, a preclinical stage company discovering and developing bispecific antibody therapeutics for the treatment of cancer.
  • In 2013, she founded Amphivena Therapeutics and served as the company's President and Chief Executive Officer through the end of 2019.
  • "We are delighted to welcome Jeanmarie to Pathios to help us to deliver on the promise of targeting GPR65 as a critical innate immune checkpoint in solid tumours," said Stuart Hughes, Ph.D., Chief Executive Officer of Pathios Therapeutics.